The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars.

Thomas Bo JensenDorthe BartelsEva Aggerholm SædderBirgitte Klindt PoulsenStig Ejdrup AndersenMette Marie H ChristensenLars NielsenHanne Rolighed Christensen

Published in: European journal of clinical pharmacology (2019)

We believe that a thorough preparation and an organizational setting supporting the implementation is crucial for the successful implementation. This same implementation model will be used for future biosimilars.

Keyphrases

primary care
healthcare
quality improvement
rheumatoid arthritis
ankylosing spondylitis
mass spectrometry
simultaneous determination